This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
Cytomegalovirus (CMV)	Bone marrow stromal cell antigen 2 (BST2; CD317)	*In vitro* studies suggest inhibiting BST2 could help treat CMV infection. In BST2-expressing human fibroblasts and endothelial cells, CMV entry and infection were greater than those in non–BST2-expressing controls. In primary BST2-expressing human peripheral blood monocytes, BST2 knockdown lowered CMV entry and infection compared with wild-type BST2 expression. Planned work includes testing BST2 inhibition in a macaque model of CMV infection. ***SciBX* 4(45); doi:10.1038/scibx.2011.1272** **Published online Nov. 17, 2011**	Unpatented; available for partnering	Viswanathan, K. *et al. PLoS Pathog.*; published online Nov. 3, 2011; doi:10.1371/journal.ppat.1002332 **Contact:** Klaus Früh, Oregon Health & Science University, Beaverton, Ore. e-mail: Fruehk@ohsu.edu